Research Center: The Indiana Clinical Trials Center
Location: 824 Edwards Dr suite 172, Plainfield, IN 46168
Lead Researchers: Dr. Scott Guenthner and Kimmie Eads, NP
IRB Committee: This study has been reviewed and approved by Advarra Institutional Review Board

Background

Approximately 31 million people in the US have eczema. While various medical and non-medical treatments are available, not all of them are effective for everyone and some can even cause unwanted side effects.

Researchers are hoping to find potentially better treatment methods to relieve eczema symptoms.  Recent studies have shown that a certain type of protein called IL-13 is constantly present in the skin of individuals with eczema.

Therefore, a research study at the Indiana Clinical Trials Center aims to find out the effectiveness and safety of an anti-IL-13 investigational medication in people with eczema. The study seeks men and women who currently suffer from moderate to severe eczema. Participants are required to attend 9 study visits at the research site over 15 months and will be compensated up to $675 for participating in this study.

Why Participate? 

• You may experience an improvement in your eczema symptoms.
• You will be compensated up to $675 for participating in this study.
• You will be helping to advance medical research which may provide additional treatment options for eczema.

Your Rights

• If you decide to participate in the study and later feel that you no longer wish to be part of it, you may withdraw at any time.
• Your records relating to this study and any other information received will be kept strictly confidential, except as required by law.
• Qualified health professionals will monitor your health as it relates to the study.

Who Can Participate?

• Males and females aged 12+ who are at least 88 lbs.
• Who have been diagnosed with moderate to severe eczema for at least 1 year.
• Able to attend 9 study visits at the research site over 15 months.
• Has no known serious reaction to an allergy-causing substance
• Not getting relief from current eczema treatment.